EUVIMEDEUVIMED entdecken
Open Access

ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes

Hadar Goldvaser, Rinat Yerushalmi, Raz Mutai, Iryna Kuchuk, Margarita Toker, Shani Paluch-Shimon, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Gil Bar- Sela, Ayelet Shai und 4 weitere

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07549-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Hadar Goldvaser und 15 weiteren Autor:innen. Beteiligte Einrichtung: Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY, 11553, USA. hadar7g@…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Receptors, Estrogen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsReceptors, EstrogenHumansFemaleMiddle AgedNeoplasm StagingAdultAgedBiomarkers, TumorPrognosisKaplan-Meier EstimateNeoplasm Recurrence, LocalAged, 80 and over

Stichwörter der Autor:innen

HER2 mRNAHER2-lowOncotypeRecurrence score

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY, 11553, USA. hadar7g@gmail.com.
  • Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
  • Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • The Oncology Institute, Meir Medical Center, Tel-Aviv University, Kfar Saba, Israel.
  • Soroka University Medical Center, Beer Sheva, Israel.
  • Faculty of Medicine, Ben Gurion University, Beer Sheva, Israel.

Förderung

  • NCI NIH HHS

Zitieren

APA

Goldvaser, H., Yerushalmi, R., Mutai, R., Kuchuk, I., Toker, M., Paluch-Shimon, S., Drumea, K., Evron, E., Sonnenblick, A., Gal-Yam, E., Sela, G. B., Shai, A., Merose, R., Bareket-Samish, A., Soussan-Gutman, L., & Stemmer, S. M. (2025). ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07549-7

Vancouver

Goldvaser H, Yerushalmi R, Mutai R, Kuchuk I, Toker M, Paluch-Shimon S, et al. ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07549-7

BibTeX
@article{Goldvaser2025,
  author = {Goldvaser, Hadar and Yerushalmi, Rinat and Mutai, Raz and Kuchuk, Iryna and Toker, Margarita and Paluch-Shimon, Shani and Drumea, Karen and Evron, Ella and Sonnenblick, Amir and Gal-Yam, Einav and Sela, Gil Bar- and Shai, Ayelet and Merose, Rotem and Bareket-Samish, Avital and Soussan-Gutman, Lior and Stemmer, Salomon M},
  title = {ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07549-7}
}
Kostenlos starten →